成人胶质母细胞瘤分次立体定向再照射后的复发模式
该回顾性研究分析了2010年10月至2020年12月在洛林癌症研究所接受CyberKnife®分次立体定向再照射(25 Gy/5次)的62例胶质母细胞瘤复发患者的复发位置。再照射后复发位置为野外43.5%、边缘40.3%、野内16.1%。GTV-PTV边距1 mm(对比2-3 mm,HR=0.38[0.15-0.95],p=0.037)和PTV体积≥36 cc(HR=5.18[1.06-25.3],p=0.042)与边缘复发显著相关;初始治疗时年龄≥60岁(HR=3.06[1.17-8.01],p=0.023)和既往复发≥1次(HR=5.29[1.70-16.5],p=0.004)与野外复发显著相关。再照射后中位无进展生存期为3.4个月,自诊断和自再照射的中位总生存期分别为25.7个月和10.8个月。
要点
- 再照射后复发以野外(43.5%)和边缘(40.3%)为主,野内仅16.1%。
- GTV-PTV边距1 mm和PTV体积≥36 cc与边缘复发显著相关。
- 年龄≥60岁和既往复发≥1次与野外复发显著相关。
核心结论
- 采用25 Gy/5次的分次立体定向再照射治疗胶质母细胞瘤复发可提供良好的局部控制。
研究设计与样本
- 回顾性分析2010年10月至2020年12月在洛林癌症研究所接受CyberKnife®分次立体定向再照射(25 Gy/5次)的胶质母细胞瘤复发患者数据,共62例。
- 将再照射后复发影像与立体定向放疗计划扫描匹配以确定复发位置。
主要发现
- 再照射后复发位置为野外43.5%、边缘40.3%、野内16.1%(N=62)。
- GTV-PTV边距1 mm(对比2-3 mm,HR=0.38[0.15-0.95],p=0.037)和PTV体积≥36 cc(HR=5.18[1.06-25.3],p=0.042)与边缘复发显著相关。
- 初始治疗时年龄≥60岁(HR=3.06[1.17-8.01],p=0.023)和既往复发≥1次(HR=5.29[1.70-16.5],p=0.004)与野外复发显著相关。
- 自再照射的中位无进展生存期为3.4个月,自诊断和自再照射的中位总生存期分别为25.7个月和10.8个月。
关键数值与推荐
- 再照射方案为25 Gy分5次,采用CyberKnife®设备。
- GTV-PTV边距1 mm对比2-3 mm与边缘复发相关(HR=0.38[0.15-0.95],p=0.037)。
- PTV体积≥36 cc与边缘复发相关(HR=5.18[1.06-25.3],p=0.042)。
- 初始治疗时年龄≥60岁与野外复发相关(HR=3.06[1.17-8.01],p=0.023)。
- 既往复发≥1次与野外复发相关(HR=5.29[1.70-16.5],p=0.004)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastomas all eventually relapse after initial treatment, and an option to treat these recurrences is fractionated stereotactic reirradiation (fSRT). The location of recurrences following reirradiation has not been studied for fSRT delivered by a dedicated stereotactic device. We aimed to analyze these locations to better elucidate safety margins, dose and fractionation regimens. METHODS: We retrospectively analyzed the data of patients with glioblastoma recurrence that had been reirradiated by fSRT in October 2010-December 2020, in 25 Gy in 5 fractions delivered by a CyberKnife® at Institut de Cancérologie de Lorraine. We matched the images of the post-fSRT relapse with the stereotactic radiation treatment planning scan to determine the relapse location. RESULTS: The location of recurrences after fSRT was "out-field" in 43.5%, "marginal" in 40.3%, and "in-field" in 16.1% of patients (N = 62). A GTV-PTV margin of 1 mm (versus 2-3 mm, HR = 0.38 [0.15-0.95], p = 0.037) and a PTV volume of ≥ 36 cc (HR = 5.18 [1.06-25.3], p = 0.042) were significantly associated with the "marginal" recurrences. Being ≥ 60 years old at initial treatment (HR = 3.06 [1.17-8.01], p = 0.023) and having one or more previous recurrences (HR = 5.29 [1.70-16.5], p = 0.004) were significantly associated with "out-field" recurrences. The median PFS from fSRT was 3.4 months, and OS from diagnosis and from fSRT were 25.7 and 10.8 months respectively. CONCLUSION: Reirradiation of glioblastoma recurrence by fSRT with 25 Gy in 5 fractions provides good local control.
引用
- Margulies A, Sahki N, Rech F, et al. Pattern of recurrence after fractionated stereotactic reirradiation in adult glioblastoma. Radiat Oncol. 2025. PMID: 40022217. doi:10.1186/s13014-025-02611-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。